biostudies-literatureShah VMBrenden-Colson Center for Pancreatic CareBrenden-Colson Center Foundation and Oregon State University College of PharmacyNCI NIH HHS2651https://www.ebi.ac.uk/biostudies/studies/S-EPMC10747591biostudies-literatureUnknown15(12)Pancreatic cancer remains a formidable challenge due to limited treatment options and its aggressive nature. In recent years, the naturally occurring anticancer compound juglone has emerged as a potential therapeutic candidate, showing promising results in inhibiting tumor growth and inducing cancer cell apoptosis. However, concerns over its toxicity have hampered juglone's clinical application. To address this issue, we have explored the use of polymeric micelles as a delivery system for juglone in pancreatic cancer treatment. These micelles, formulated using Poloxamer 407 and D-α-Tocopherol polyethylene glycol 1000 succinate, offer an innovative solution to enhance juglone's therapeutic potential while minimizing toxicity. In-vitro studies have demonstrated that micelle-formulated juglonPharmaceuticsMicelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment.PMC10747591P30 CA069533U01 CA224012U01CA224012DoD PA210068R01 CA186241Brody JRPelz CAl-Fatease ASmith ATsuda MMacPherson KChin KYardimci GGKrieger MSheppard BCDaniel CJRizvi SAlani AWEng JShah VMSears RCLanger EMMunks MWfalseMicelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment.Pancreatic cancer remains a formidable challenge due to limited treatment options and its aggressive nature. In recent years, the naturally occurring anticancer compound juglone has emerged as a potential therapeutic candidate, showing promising results in inhibiting tumor growth and inducing cancer cell apoptosis. However, concerns over its toxicity have hampered juglone's clinical application. To address this issue, we have explored the use of polymeric micelles as a delivery system for juglone in pancreatic cancer treatment. These micelles, formulated using Poloxamer 407 and D-α-Tocopherol polyethylene glycol 1000 succinate, offer an innovative solution to enhance juglone's therapeutic potential while minimizing toxicity. In-vitro studies have demonstrated that micelle-formulated juglon2023-01-01T00:00:00Z2023 Nov2026-04-08T14:46:27.693Z2025-04-19T14:34:24.943ZS-EPMC107475913813999310.3390/pharmaceutics15122651